ReviewAnnals of hematology2026

Current evidence and strategies for bridging therapy in CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphomas.

Jie Lv et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.